Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 22, 2007, Pages 6234-6238

  Kim, Hwan Mook ^a   Hong, Sung Hee ^b   Kim, Myung Sook ^b   Lee, Chang Woo ^a   Kang, Jong Soon ^a   Lee, Kiho ^a   Park, Song Kyu ^a   Han, Jeung Whan ^c   Lee, Hee Yoon ^d   Choi, Yongseok ^e   Kwon, Ho Jeung ^b   Han, Gyoonhee ^b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Yonsei University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e Korea University   (South Korea)

Author keywords

Anticancer chemotherapy; Docking model; Enzyme inhibitor; Growth inhibition; HDAC; Histone deacetylase; In vivo xenograft model

Indexed keywords

APICIDIN; FR 901228; HISTONE DEACETYLASE INHIBITOR; LACTAM DERIVATIVE; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VIVO STUDY; MOUSE; NONHUMAN; RING CLOSING METATHESIS; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; LACTAMS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35148888600     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.034     Document Type: Article

References (19)

1. Wu J., and Grunstein M. Trends Biochem. Sci. 25 (2000) 619
2. Kouzarides T. Curr. Opin. Genet. Dev. 9 (1999) 40
3. Archer S.Y., and Hodin R.A. Curr. Opin. Genet. Dev. 9 (1999) 171
4. Saunders N.A., Popa C., Serewko M.M., Jones S.J., Dicker A.J., and Dahler A.L. Expert Opin. Invest. Drugs 8 (1999) 1611
5. Johnstone W.R. Nat. Rev. 1 (2002) 287
6. Yoshida M., Kijima M., Akita M., and Beppu T. J. Biol. Chem. 265 (1990) 17174
7. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., Kwon H.K., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Cancer Res. 60 (2000) 6068
8. Kijima M., Yoshida M., Sugita K., Horinouchi S., and Beppu T. J. Biol. Chem. 268 (1993) 22429
9. Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., and Shimomura K. J. Antibiot. 47 (1994) 315
10. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Cancer Res. 60 (2000) 5165
11. Kim H.M., Lee K., Park B.W., Ryu D.K., Kim K., Lee C.W., Park S.-K., Han J.W., Lee H.Y., and Han G. Bioorg. Med. Chem. Lett. 16 (2006) 4068
12. Kim H.M., Ryu D.K., Choi Y., Park B.W., Lee K., Han S.B., Lee C.-W., Kang M.-R., Kang J.S., Boovanahalli S.K., Park S.-K., Han J.W., Chun T.-G., Lee H.-Y., Nam K.-Y., Choi E.H., and Han G. J. Med. Chem. 50 (2007) 2737
13. For QSAR study of various cap groups, see:. Juvale D.C., Kulkarni V.V., Deokar H.S., Wash N.K., Padhye S.B., and Kulkarrni V.M. Org. Biomol. Chem 4 (2006) 2858
14. HDAC inhibition assay: HDAC fluorescent activity assays using a Fluror de LysTM Substrate (Biomol, Plymouth Meeting, PA), which contains an acetylated lysine side chain, were performed according to manufacturer's instructions. In brief, HeLa nuclear extracts, which were used as an HDAC enzyme source, were incubated at 25 °C with 250 mM of Fluror de LysTM Substrate and various concentrations of each sample. Reactions were stopped after 20 min with Fluror de LysTM Developer and fluorescence was measured using a microplate spectrofluorometer (LS 50B, Perkin-Elmer) with excitation at 360 nm and emission at 460 nm.
15. +).
16. Papazisis K.T., Geromichalos G.D., Dimitriadis K.A., and Kortsaris A.H. J. Immunol. Methods 208 (1997) 151
17. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 107
18. 2 × π/6.
19. McMartin C., and Bohacek R.S. J. Comput. Aided Mol. Des. 11 (1997) 333